RIBOLIFE-B (06938) has announced the successful achievement of the third key milestone in its research and development partnership with Boehringer Ingelheim (BI). The collaboration focuses on creating innovative treatments for liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). MASH is a serious and progressive form of fatty liver disease that can lead to fibrosis, cirrhosis, liver failure, and liver cancer, affecting over 200 million people worldwide. Despite the growing burden of the disease, there remains a significant need for effective medications that can help prevent disease progression and support liver health. This partnership aims to expand the pipeline of potential future treatment options for MASH patients. Reaching this milestone further strengthens the company's position as a strategic partner for global pharmaceutical firms and highlights the commercial potential of its siRNA platform.